Intranasal vaccines are back in the spotlight as highly pathogenic avian influenza spreads among birds and spills over into mammals, including recent cases in dairy and poultry workers. In this episode of In Vivo, senior pharma and biotech reporter David Wild talks with Chad Costley, CEO of BlueWillow Biologics and Meagan Deming, an infectious disease researcher at the University of Maryland School of Medicine about a novel intranasal recombinant H5 flu vaccine that aims to stop infection at the gate by building mucosal immunity in the nose. They discuss recent Phase I data, pandemic‑flu preparedness, BARDA/NIH funding realities, and how BlueWillow's NanoVax platform could extend to other major respiratory threats, including TB.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related